Evidence map›Paper›PMID 32997393›Full record

ArticleAnnals of clinical and translational neurology2020

Targeting foam cell formation in inflammatory brain diseases by the histone modifier MS-275.

Bettina Zierfuss, Isabelle Weinhofer, Agnieszka Buda, Niko Popitsch, Lena Hess, Verena Moos, Simon Hametner, Stephan Kemp, Wolfgang Köhler, Sonja Forss-Petter and 2 more

Open access · goldAbstract read
In one paragraph

Article in Annals of clinical and translational neurology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 3 countries.

Bettina ZierfussDepartment of Pathobiology of the Nervous System, Centre for Brain Research, Medical University of Vienna, Vienna, 1090, Austria.ORCID 0000-0002-5357-2630
Isabelle WeinhoferDepartment of Pathobiology of the Nervous System, Centre for Brain Research, Medical University of Vienna, Vienna, 1090, Austria.ORCID 0000-0002-8455-2069
Agnieszka BudaDepartment of Pathobiology of the Nervous System, Centre for Brain Research, Medical University of Vienna, Vienna, 1090, Austria.ORCID 0000-0002-1996-3662
Niko PopitschInstitute of Molecular Biotechnology, Vienna, 1030, Austria.
Lena HessDivision of Cell and Developmental Biology, Center for Anatomy and Cell Biology, Medical University of Vienna, Vienna, 1090, Austria.
Verena MoosDivision of Cell and Developmental Biology, Center for Anatomy and Cell Biology, Medical University of Vienna, Vienna, 1090, Austria.
Simon HametnerDepartment of Neuropathology and Neurochemistry, Medical University of Vienna, Vienna, 1090, Austria.
Stephan KempLaboratory Genetic Metabolic Diseases, Amsterdam UMC, Amsterdam Gastroenterology & Metabolism, Amsterdam Neuroscience, University of Amsterdam, Amsterdam, 1105AZ, The Netherlands.
Wolfgang KöhlerDepartment of Neurology, University of Leipzig Medical Centre, Leukodystrophy Clinic, Leipzig, 04103, Germany.
Sonja Forss-PetterDepartment of Pathobiology of the Nervous System, Centre for Brain Research, Medical University of Vienna, Vienna, 1090, Austria.
Christian SeiserDivision of Cell and Developmental Biology, Center for Anatomy and Cell Biology, Medical University of Vienna, Vienna, 1090, Austria.
Johannes BergerDepartment of Pathobiology of the Nervous System, Centre for Brain Research, Medical University of Vienna, Vienna, 1090, Austria.ORCID 0000-0003-0182-2658
Medical University of Vienna · ATAmsterdam Neuroscience · NLInstitute of Molecular Biotechnology · ATUniversity Hospital Leipzig · DE

Funding

Austrian Science Fund FWF DOC 33Austrian Science Fund FWF P 28705
6 · The paper itself

Abstract

objectiveTo assess class I-histone deacetylase (HDAC) inhibition on formation of lipid-accumulating, disease-promoting phagocytes upon myelin load in vitro, relevant for neuroinflammatory disorders like multiple sclerosis (MS) and cerebral X-linked adrenoleukodystrophy (X-ALD).

methodsImmunohistochemistry on postmortem brain tissue of acute MS (n = 6) and cerebral ALD (n = 4) cases to analyze activation and foam cell state of phagocytes. RNA-Seq of in vitro differentiated healthy macrophages (n = 8) after sustained myelin-loading to assess the metabolic shift associated with foam cell formation. RNA-Seq analysis of genes linked to lipid degradation and export in MS-275-treated human HAP1 cells and RT-qPCR analysis of HAP1 cells knocked out for individual members of class I HDACs or the corresponding enzymatically inactive knock-in mutants. Investigation of intracellular lipid/myelin content after MS-275 treatment of myelin-laden human foam cells. Analysis of disease characteristic very long-chain fatty acid (VLCFA) metabolism and inflammatory state in MS-275-treated X-ALD macrophages.

resultsEnlarged foam cells coincided with a pro-inflammatory, lesion-promoting phenotype in postmortem tissue of MS and cerebral ALD patients. Healthy in vitro myelin laden foam cells upregulated genes linked to LXRα/PPARγ pathways and mimicked a program associated with tissue repair. Treating these cells with MS-275, amplified this gene transcription program and significantly reduced lipid and cholesterol accumulation and, thus, foam cell formation. In macrophages derived from X-ALD patients, MS-275 improved the disease-associated alterations of VLCFA metabolism and reduced the pro-inflammatory status of these cells.

interpretationThese findings identify class I-HDAC inhibition as a potential novel strategy to prevent disease promoting foam cell formation in CNS inflammation.

Indexed as

AdrenoleukodystrophyInflammationMultiple SclerosisAcute DiseaseAdultAutopsyBenzamidesFoam CellsGene Expression ProfilingHistone Deacetylase InhibitorsHumansImmunohistochemistryMiddle AgedPyridinesSequence Analysis, RNAYoung AdultBenzamidesentinostatHistone Deacetylase InhibitorsPyridines

Identifiers

PMID32997393
PMCPMC7664285
OpenAlexW3090799598

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.